ReviewExpert opinion on therapeutic targets2013
Targeting CCL5 in inflammation.
Review in Expert opinion on therapeutic targets, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 231 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
231 citing papers in PubMed, 4 syntheses or guidelines pooled it, 367 citations in OpenAlex.
- Methylation profile of individuals with sickle cell trait.Epigenetics · 2025Pooled it
- A Comprehensive Review of Kimura Disease.Head and neck pathology · 2025Pooled it
- Genetic polymorphisms as multi-biomarkers in severe acute respiratory syndrome (SARS) by coronavirus infection: A systematic review of candidate gene association studies.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021Pooled it
- Host genetic susceptibility to mycetoma.PLoS neglected tropical diseases · 2020Pooled it
- Serum extracellular vesicle RNA profiles in long COVID: insights from exercise-induced gene modulation.Scientific reports · 2026Trial
- Safety and Anti-Inflammatory Effects of Engineered Extracellular Vesicles (ILB-202) for NF-κB Inhibition: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Trial.Journal of extracellular vesicles · 2025Trial
- PIWIL2 drives stroke progression via modulation of NF-κB signaling.Molecular therapy. Nucleic acids · 2026Article
- CB2 Receptor Activation Attenuates IL-1β-Induced Inflammatory Transcriptomic Networks in Human Gingival Fibroblasts.Pharmaceuticals (Basel, Switzerland) · 2026Article
- CCL5 exposure promotes acute and transient megakaryopoiesis and hematopoietic progenitor expansion.Stem cell reports · 2026Article
- Notch signaling regulates the secretion of pro-metastatic factors in extracellular vesicles in liposarcoma.Cancer letters · 2026Article
- The Role of Interleukin-18 After Spinal Cord Injury: Mechanisms and Therapeutic Potential.Cells · 2026Review
- Intranasal infection of Rift Valley fever virus in the ferret model suggests multiple routes of neuroinvasion with consequential encephalitis and ophthalmitis.Scientific reports · 2026Article
- Exosomal Protein Biomarkers for Predicting Early Neurological Deterioration Following Intravenous Thrombolysis in Acute Ischemic Stroke.Translational stroke research · 2026Article
- CCL5 promotes colon cancer progression via PI3K/AKT signaling and is negatively regulated by STAT1.Journal of gastrointestinal oncology · 2026Article
- Machine learning predictions surpass individual mRNAs as a proxy of single-cell protein expression.Genome biology · 2026Article
- Plasma Extracellular Vesicles (EVs)-Mediated Immune Dysregulation and Chronic Inflammation in Autism Spectrum Disorder.Cellular and molecular neurobiology · 2026Article
- Article
- Integrative multi-omics analysis identifies C-type lectin CNVs as functional targets for breeding mastitis-resistant dairy goats.Animal microbiome · 2026Article
- Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer.Nature biomedical engineering · 2026Article
- Heterologous saRNA prime - multivalent protein boost strategy induces broad and durable immunity against SARS-CoV-2 and MERS-CoV.Scientific reports · 2026Article
171 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
Abstract
introductionChemokines play important roles in inflammation and in immune responses. This article will discuss the current literature on the C-C chemokine ligand 5 (CCL5), and whether it is a therapeutic target in the context of various allergic, autoimmune or infectious diseases. AREAS COVERED: Small-molecule inhibitors, chemokine and chemokine receptor-deficient mice, antibodies and modified chemokines are the current tools available for CCL5 research, and there are several ongoing clinical trials targeting the CCL5 receptors, CCR1, CCR3 and CCR5. There are fewer studies specifically targeting the chemokine itself and clinical studies with anti-CCL5 antibodies are still to be carried out. EXPERT OPINION: Although clinical trials are strongly biased toward HIV treatment and prevention with blockers of CCR5, the therapeutic potential for CCL5 and its receptors in other diseases is relevant. Overall, it is not likely that specific targeting of CCL5 will result in new adjunct strategies for the treatment of infectious diseases with a major inflammatory component. However, targeting CCL5 could result in novel therapies for chronic inflammatory diseases, where it may decrease inflammatory responses and fibrosis, and certain solid tumors, where it may have a role in angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.